Beigene (BGNE) Sets New 12-Month High at $146.44

Beigene Ltd (NASDAQ:BGNE)’s share price reached a new 52-week high on Wednesday . The company traded as high as $146.44 and last traded at $135.66, with a volume of 355100 shares. The stock had previously closed at $135.66.

A number of equities analysts have weighed in on the stock. BidaskClub upgraded shares of Beigene from a “hold” rating to a “buy” rating in a research report on Wednesday, January 31st. ValuEngine upgraded shares of Beigene from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Maxim Group set a $120.00 price objective on shares of Beigene and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Zacks Investment Research upgraded shares of Beigene from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Finally, Cowen restated a “buy” rating on shares of Beigene in a research report on Monday, December 11th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $96.67.

The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33.

In other news, CEO John Oyler sold 85,906 shares of the stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $84.66, for a total value of $7,272,801.96. Following the completion of the sale, the chief executive officer now directly owns 332,697 shares in the company, valued at $28,166,128.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bros. Advisors Lp Baker bought 1,980,198 shares of Beigene stock in a transaction dated Thursday, January 18th. The stock was acquired at an average price of $101.00 per share, with a total value of $199,999,998.00. The disclosure for this purchase can be found here. Insiders sold 301,670 shares of company stock valued at $27,418,711 over the last quarter. Company insiders own 19.90% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Quantbot Technologies LP purchased a new stake in shares of Beigene in the third quarter valued at about $160,000. Tower Research Capital LLC TRC purchased a new stake in shares of Beigene in the fourth quarter valued at about $182,000. Comerica Bank purchased a new stake in shares of Beigene in the fourth quarter valued at about $246,000. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Beigene in the third quarter valued at about $248,000. Finally, Mackenzie Financial Corp purchased a new stake in shares of Beigene in the fourth quarter valued at about $250,000. Institutional investors and hedge funds own 49.35% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Beigene (BGNE) Sets New 12-Month High at $146.44” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://stocknewstimes.com/2018/02/23/beigene-bgne-sets-new-12-month-high-at-146-44.html.

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply